Oncopeptides announces that two abstracts on multiple myeloma have been accepted by the 2020 ASCO Annual Meeting
STOCKHOLM — May 13, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that two abstracts with data in multiple myeloma have been accepted by the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. One of the abstracts relates to the pivotal phase 2 HORIZON study evaluating melflufen in relapsed refractory multiple myeloma (RRMM) patients. The abstracts are now available online.Melflufen (melphalan flufenamide) is a first-in-class anticancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. The lead drug candidate is in late stage